References
- Willemze R, Jaffe E F, Burg G, Cerroni L, Berti E, Swerdlow S H, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785
- Roberts W C, Glancy D L, DeVita V T. Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides) a study of 196 autopsy cases. Am J Cardiol 1968; 22: 85–107
- Youn H K, Lui H L, Mraz-Gerhard S, Varghese A, Hoppe R T. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Arch Dermatol 2003; 139: 857–866
- Enblad G, Hagberg H, Erlanson M, Lundin J, Porwit MacDonald A, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920–2924
- Saricaoglu H, Tunali Ş, Őzkalemkaş F, Ali R, Bülbül E, Aydoğan K, et al. Mycosis fungoides with central nervous system involvement. Int J Dermatol 2000; 39: 874–875
- Lippert B M, Höft S, Teymoortash A, Wiedow O, Rövert J, Werner J A. Mycosis fungoides of the larynx: case report and review of the literature. Otolarygol Polska 2002; 6: 661–667
- Carpio-O'Donovan R, Freeman C. Brainstem involvement with mycosis fungoides: an unusual central nervous system complication. Am J Neuroradiol 2002; 23: 533–534
- MacGee W. Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study. Vichows Archiv A Pathol Anat Histopathol 1991; 419: 183–189
- Cooper D L, Sinard J H, Edelson R L, Flynn S D. Cardiogenic shock due to progression of cutaneous T-cell lymphoma. South Med J 1994; 87: 89–94
- Lenihan D J, Alencar A J, Yang D, Kurzrock R, Keating M R, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004; 104: 655–658
- Cersosimo R J. Monoclonal antibodies in the treatment of cancer: Part 2. Am J Health Syst Pharm 2003; 60: 1631–1641
- Ravandi F, O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24: 718–725
- Lundin J, Kennedy B, Dearden C, Dyer M JS, Österborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 2005; 105: 4148–4149
- Kennedy G A, Seymour J F, Wolf M, Januszewicz H, Davison J, McCormack C, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003; 71: 250–256
- Basquira A L, Beretta A R, García J J, Palazzo E D. Coronary ischaemia related to alemtuzumab therapy. Ann Oncol 2004; 15: 539–540
- Swaminathan A, Tzamaloukas A H, Clark D A, McLemore J L, McKinney D R, Crooks L A. Oliguric acute renal failure in mycosis fungoides with lymphomatous infiltrates in the kidneys. Int Urol Nephrol 2002; 33: 149–155
- Lundin J, Hogberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003; 101: 4267–4272